ReNeuron gets target upgrade after full year numbers
"The group is at an exciting point in its development with a strong stem cell platform grounded in IP"
Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 2 of 15
ReNeuron focused fully on exosomes platform
Cash deposits currently are £14.5mln, giving a runway until mid-calendar 2023 at least
ReNeuron unveils board reshuffle as part of business refocus
Martin Walton joins as a non-executive director and "brings a wealth of relevant experience in the life sciences sector”
ReNeuron chief executive steps down after strategy change
Chairman Iain Ross will assume responsibility for running the company, supported by chief financial officer Catherine Isted
ReNeuron to focus on in-demand Exosome drug delivery technology
It is also looking to find a partner for its human retinal progenitor cells programme
ReNeuron makes progress with Fosun technology transfer
Fosun will spearhead the development of the CTX drug product for stroke disability in the Greater China region
ReNeuron re-appoints Corteling as vice president of research
Corteling has 24 years of experience in medical research and drug discovery, across the academia, biotechnology, and pharmaceutical industries
ReNeuron CEO says company is in the right place, at the right time, with the right technology
CEO Olav Hellebø was bullish about the potential of the company's exosomes research
ReNeuron jumps 13% as UCL study flags commercial potential of company's stem cell technology
Researchers found the pluripotent stem cells can be produced at 'mas scale' as a potential off-the-shelf product
ReNeuron inks collaboration deal with University College London
ReNeuron’s chief scientific officer, Dr Stefano Pluchino, said: “This collaboration is another strong development for ReNeuron which demonstrates the uniqueness and strong translational potential of our proprietary iPSC technology platform
ReNeuron treats first patient in mid-stage trials for eye disease candidate
The group also said that Catherine Isted has now joined the company as a chief financial officer
ReNeuron Group PLC shares soar on impressive data from latest breakthrough
The company's technology could help unlock treatments for stroke, Parkinson’s and Huntington’s diseases
ReNeuron hails “clear pre-clinical proof-of-concept” for exosomes technology
The ability to deliver therapeutic proteins to a part of the brain associated with stroke, Parkinson's Disease and Huntington's Disease could offer a breakthrough for doctors - though the company is at the very early stages of the R&D proce
Proactive news headlines: ReNeuron, Live Company, Coro Energy....
A summary of the small-cap stories on the Proactive website today
ReNeuron 'pleased to be back on track' with phase IIa eye disease trial
With the remaining people in the study expected to be treated by the end of the year, researchers are slated to present early efficacy data from the expansion cohort in the first quarter of 2022
ReNeuron appoints chief financial officer
Catherine Isted spent 12 years at partner level in two leading healthcare banking teams undertaking multiple initial public offerings and follow-on fundraisings
ReNeuron expects data in fourth quarter on two programmes
"Our exosome and iPSC platforms have also progressed well during the period"
ReNeuron appoints Iain Ross as non-executive chairman
"We welcome his support as we enter into a period where we expect to reach important, data-driven value inflection points across our programmes over the next 12 months," said CEO Olav Hellebø
ReNeuron now expects hRPC study data in fourth quarter
ReNeuron said it has temporarily halted dosing further patients until it finds the cause of an infection in the latest subject
Archive
Proactive news headlines: ReNeuron, Thor Mining, Critical Metals…
A look at some of the day's major headlines from the Proactive newswire